Ventas

VTRNYSEUSD

THESIS ALERT

Email me when the VTR thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$90.42
+$0.08 (+0.09%)Today 1M +10.21%
After hours$90.28−0.15%

Updated Nov 11, 4:03 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$90.34
Prior regular-session close from the quote source.
$89.38–$90.60
Regular-session low and high so far today.
2.4M
Regular-session shares traded · Nov 11, 4:03 PM ET.
Feb 4 projected
Projected for 2027-02-04 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
$73.82–$101.60
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own VTR if Ventas builds durable cash flow and dividend capacity by owning diversified healthcare real estate (senior housing, outpatient/research, and triple-net medical properties) and using scale, operator partnerships and a third-party capital platform to acquire accretive.

VTR price history

Latest price$90.42Today+$0.08 (+0.09%)
VTR +8.83%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • Aging-demographic-driven demand and low near-term senior-housing supply will keep occupancy/rent trends positive for SHOP, supporting continued top-line and NOI growth that translates into rising consolidated revenue.StrengtheningMateriality: High

    Revenue rose from $3.8288B (2021) to $5.83398B (2025), showing sustained top-line growth (revenue field history). If true, revenue and recurring cash flows grow organically and through selective buys, justifying reinvestment and dividend support; if false, revenue stalls and the REIT faces valuation and dividend pressure.

    Watch: A sustained nationwide pickup in senior-housing construction starts reversing the 'low supply' argument.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Revenue rose from $3.8288B (2021) to $5.83398B (2025), showing sustained top-line growth (revenue field history).

    Open source ↗
  • Ventas' scale, operator relationships and its VIM third-party capital platform allow it to acquire and operate accretive senior-housing and healthcare assets and generate fee/promote income, which increases operating cash flow and diversifies cash sources beyond property NOI.HoldingMateriality: High

    Operating cash flow increased from $1.026116B (2021) to $1.646726B (2025), showing growing cash generation capacity (operating_cash_flow field). If VIM and scale continue to produce fee income and accretive deals, operating cash flow and dividend coverage improve; if JV/platform deals stall or prove dilutive, FCF will be weaker and dividend growth limited.

    Watch: Competition for healthcare assets from other REITs and private capital pushes purchase cap rates lower (higher prices) making deals less accretive.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Operating cash flow increased from $1.026116B (2021) to $1.646726B (2025), showing growing cash generation capacity (operating_cash_flow field).

    Open source ↗
  • The recovery and expansion of net income reflect normalization of operations and scale benefits; maintaining stable property valuations and controlled interest expense will keep net income positive and support EPS and dividend capacity.StrengtheningMateriality: Medium

    Net income moved from negative in 2022 (-$40.931M) and 2023 (-$30.297M) to positive $88.351M (2024) and $261.518M (2025) (net_income field history). Sustained positive net income enables retained earnings and easier dividend coverage under REIT cash distributions; a reversal would signal operating stress or mark-to-market impairment risk.

    Watch: A broad cap-rate expansion driving impairments or large non-cash write-downs on real-estate investments.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Net income moved from negative in 2022 (-$40.931M) and 2023 (-$30.297M) to positive $88.351M (2024) and $261.518M (2025) (net_income field.

    Open source ↗
  • Ventas' large asset base and balance-sheet scale provide optionality to acquire at scale, manage through cycles and access capital to execute the strategy.StrengtheningMateriality: Medium

    Total assets increased to $27,591,945,000 as of Dec 31, 2025 (assets field), reflecting a large diversified portfolio and scale. If balance-sheet scale and liquidity persist, management can buy assets opportunistically and smooth dividend payments; if the balance sheet weakens, the company will be forced to sell or suspend growth and possibly cut distributions.

    Watch: A sharp fall in property valuations leading to balance-sheet impairments and covenant breaches.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Total assets increased to $27,591,945,000 as of Dec 31, 2025 (assets field), reflecting a large diversified portfolio and scale.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Aging-demographic-driven demand and low near-term senior-housing supply will keep occupancy/rent trends positive for SHOP, supporting continued top-line and NOI growth that translates into rising consolidated revenue. If true, revenue and recurring cash flows grow organically and through selective buys, justifying reinvestment and dividend support; if false, revenue stalls and the REIT faces valuation and dividend pressure.

Ventas' scale, operator relationships and its VIM third-party capital platform allow it to acquire and operate accretive senior-housing and healthcare assets and generate fee/promote income, which increases operating cash flow and diversifies cash sources beyond property NOI. If VIM and scale continue to produce fee income and accretive deals, operating cash flow and dividend coverage improve; if JV/platform deals stall or prove dilutive, FCF will be weaker and dividend growth limited.

The recovery and expansion of net income reflect normalization of operations and scale benefits; maintaining stable property valuations and controlled interest expense will keep net income positive and support EPS and dividend capacity. Sustained positive net income enables retained earnings and easier dividend coverage under REIT cash distributions; a reversal would signal operating stress or mark-to-market impairment risk.

Ventas' large asset base and balance-sheet scale provide optionality to acquire at scale, manage through cycles and access capital to execute the strategy. If balance-sheet scale and liquidity persist, management can buy assets opportunistically and smooth dividend payments; if the balance sheet weakens, the company will be forced to sell or suspend growth and possibly cut distributions.

All standing thesis claims
Original report summary

Ventas builds durable cash flow and dividend capacity by owning diversified healthcare real estate (senior housing, outpatient/research, and triple-net medical properties) and using scale, operator partnerships and a third-party capital platform to acquire accretive.

Evidence assessed Nov 7, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Ventas

Where the evidence on Ventas stands: Holding on the latest evidence (Nov 7, 2026). Of its 4 thesis points, 3 strengthening and 1 holding.

Bull case: what the evidence supports

  • Aging-demographic-driven demand and low near-term senior-housing supply will keep occupancy/rent trends positive for SHOP, supporting continued top-line and NOI growth that translates into rising consolidated revenue.

    sec.gov ↗

  • Ventas' scale, operator relationships and its VIM third-party capital platform allow it to acquire and operate accretive senior-housing and healthcare assets and generate fee/promote income, which increases operating cash flow and diversifies cash sources beyond property NOI.

    sec.gov ↗

  • The recovery and expansion of net income reflect normalization of operations and scale benefits; maintaining stable property valuations and controlled interest expense will keep net income positive and support EPS and dividend capacity.

    sec.gov ↗

  • Ventas' large asset base and balance-sheet scale provide optionality to acquire at scale, manage through cycles and access capital to execute the strategy.

    sec.gov ↗

Bear case: what would count against it

  • A sustained nationwide pickup in senior-housing construction starts reversing the 'low supply' argument.

    sec.gov ↗

  • Competition for healthcare assets from other REITs and private capital pushes purchase cap rates lower (higher prices) making deals less accretive.

    sec.gov ↗

  • A broad cap-rate expansion driving impairments or large non-cash write-downs on real-estate investments.

    sec.gov ↗

Thesis-Break Engine

What has broken in Ventas’s thesis

Each break OptimistFi flagged on Ventas, dated — with what has historically followed the same kind of break across the market, not a forecast for Ventas.

peers+15%-20%-2%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical -2% path vs comparable companies over six months, inside the middle-half range (+15% to -20%). A base rate, not a forecast.
  • CEO / officer changecondition set before this filing

    Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Ventas filed an SEC 8-K on 2026-10-27: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Director or principal officer change.

    Ventas filed an SEC 8-K on 2026-09-15: Director or principal officer change. It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    Ventas filed an SEC 8-K on 2026-07-29: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • A sustained nationwide pickup in senior-housing construction starts reversing the 'low supply' argument.
  • Competition for healthcare assets from other REITs and private capital pushes purchase cap rates lower (higher prices) making deals less accretive.
  • A broad cap-rate expansion driving impairments or large non-cash write-downs on real-estate investments.
  • A sharp fall in property valuations leading to balance-sheet impairments and covenant breaches.

VTR news

Loading headlines…

Financial statements

VTR income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

VTR: quick answers

When does Ventas (VTR) report earnings next?
Ventas's next results are projected for February 4, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on October 27, 2026. Earnings calendar
What is VTR's short interest?
As of October 30, 2026, 15.0M VTR shares were sold short, 2.83% of its shares outstanding, up 3.6% from the count before. At the stock's average daily volume that is 4.0 days to cover. FINRA publishes the count twice a month. VTR short interest history
Have members of Congress traded VTR?
28 trades in VTR have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed VTR trade
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.